Haberler2017 “TÜBA Ödülleri” Sahiplerini Buldu Doç. Dr. Ayata’dan “Beyin Hasarı Depolarizasyonları” Başlıklı “Akademi Ödülü Konferansı” TÜBA Başkanlık Açıklaması Doç. Dr. Ayata’dan “Akademi Ödülü Konferansı” Prof. Hamza’dan “Akademi Ödülü Konferansı” “TÜBA 2017 Ödülleri” Açıklandı TÜBA-GEBİP ve TESEP Ödülleri için 2018 Yılı Başvuruları Başladı TÜBA Asli Üyesi Prof. Savaş Uşak Üniversitesi Rektörlüğü'ne Atandı Ahmet Yesevi Üniversitesi Mütevelli Heyet Başkanı Prof. Yıldız'dan TÜBA’ya Ziyaret BEÜ Rektör V. Prof. Dr. Ali Azar'dan TÜBA’ya Ziyaret
TÜBA Session at International Congress on Oncological Sciences
Tarih: 30 EKİM 2017 Okunma Sayısı: 1018
TÜBA Session was held at the International Congress on Oncological Sciences organized by Turkish Society of Medical Oncology-TSM on September 27 – October 1 in Antalya and supported by Union for International Cancer Control – UICC and TİKA.
250 cancer scientists/specialists from 15 different countries (Central Asian Turkic Republics, Middle East and Balkan countries and neighboring countries) participated in the congress, where many topics were discussed in detail.
TÜBA Session on “Maintaining a value-based care model in the era of increasing pressures towards individualized treatment” was moderated by TÜBA Council Member and Ankara University Medical Faculty Member Prof. Taner Demirer and Former UICC President and Hacettepe University Medical Faculty Member Prof. Tezer Kutluk.
In TSMO – TUBA – UICC Joint Session, the presentations “The global framework that is shaping national strategies” by Cary Adams from Union for International Cancer Control, “Perspectives and learning from national efforts to optimize access to cancer detection, diagnosis, treatment and care” by Richard Sullivan from Institute of Cancer Policy, King’s College, and “Value-based cancer care: perspectives for the practicing oncologist” by Yeşim Eralp from Istanbul University Institute of Oncology were held.
At the TÜBA session, discussions with questions and answers were held with regional representatives from Kazakhstan, Iran, Israel, Azerbaijan, Georgia and Turkey.
At the end of the meeting, it was decided that a joint network managed by our country should be established in order to carry out scientific studies, determining cancer policies, the use of innovative therapies and biosimilar drugs and exchanging opinions.